tetano
Editor, Senior Moderator
Biomed Environ Sci
. 2022 Dec 20;35(12):1100-1105.
doi: 10.3967/bes2022.139.
Symptomatic and Asymptomatic SARS-CoV-2 Infection and Follow-up of Neutralizing Antibody Levels
Shu Juan Cui[SUP] 1 [/SUP], Yi Zhang[SUP] 2 [/SUP], Wen Jing Gao[SUP] 3 [/SUP], Xiao Li Wang[SUP] 1 [/SUP], Peng Yang[SUP] 1 [/SUP], Quan Yi Wang[SUP] 1 [/SUP], Xing Huo Pang[SUP] 1 [/SUP], Xiao Peng Zeng[SUP] 1 [/SUP], Li Ming Li[SUP] 3 [/SUP]
Affiliations
Abstract
Objective: To investigate neutralizing antibody levels in symptomatic and asymptomatic patients with coronavirus disease 2019 (COVID-19) at 6 and 10 months after disease onset.
Methods: Blood samples were collected at three different time points from 27 asymptomatic individuals and 69 symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Virus-neutralizing antibody titers against SARS-CoV-2 in both groups were measured and statistically analyzed.
Results: The symptomatic and asymptomatic groups had higher neutralizing antibodies at 3 months and 1-2 months post polymerase chain reaction confirmation, respectively. However, neutralizing antibodies in both groups dropped significantly to lower levels at 6 months post-PCR confirmation.
Conclusion: Continued monitoring of symptomatic and asymptomatic individuals with COVID-19 is key to controlling the infection.
Keywords: Asymptomatic; Neutralizing antibody; SARS-CoV-2; Symptomatic.
. 2022 Dec 20;35(12):1100-1105.
doi: 10.3967/bes2022.139.
Symptomatic and Asymptomatic SARS-CoV-2 Infection and Follow-up of Neutralizing Antibody Levels
Shu Juan Cui[SUP] 1 [/SUP], Yi Zhang[SUP] 2 [/SUP], Wen Jing Gao[SUP] 3 [/SUP], Xiao Li Wang[SUP] 1 [/SUP], Peng Yang[SUP] 1 [/SUP], Quan Yi Wang[SUP] 1 [/SUP], Xing Huo Pang[SUP] 1 [/SUP], Xiao Peng Zeng[SUP] 1 [/SUP], Li Ming Li[SUP] 3 [/SUP]
Affiliations
- PMID: 36597289
- DOI: 10.3967/bes2022.139
Abstract
Objective: To investigate neutralizing antibody levels in symptomatic and asymptomatic patients with coronavirus disease 2019 (COVID-19) at 6 and 10 months after disease onset.
Methods: Blood samples were collected at three different time points from 27 asymptomatic individuals and 69 symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Virus-neutralizing antibody titers against SARS-CoV-2 in both groups were measured and statistically analyzed.
Results: The symptomatic and asymptomatic groups had higher neutralizing antibodies at 3 months and 1-2 months post polymerase chain reaction confirmation, respectively. However, neutralizing antibodies in both groups dropped significantly to lower levels at 6 months post-PCR confirmation.
Conclusion: Continued monitoring of symptomatic and asymptomatic individuals with COVID-19 is key to controlling the infection.
Keywords: Asymptomatic; Neutralizing antibody; SARS-CoV-2; Symptomatic.